A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Graft-versus-host Disease (GVHD) Clinical Trial

Official title:
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)

Status Completed

Clinical Trial Summary

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03112603
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Completed
Phase	Phase 3
Start date	June 29, 2017
Completion date	December 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03139604` - GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease	Phase 3
Completed	`NCT02953678` - A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)	Phase 2
Completed	`NCT02614612` - Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD	Phase 1
Approved for marketing	`NCT03147742` - An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Approved for marketing	`NCT05722912` - Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD